Mortality and survival
|
18
|
8
|
15
|
6
|
3
|
2
|
NA
|
NA
|
Survival
|
2
| |
2
| |
0
| |
NA
| |
Overall survival
|
5
| |
3
| |
2
| |
NA
| |
Cause- (or disease) specific survival
|
6
| |
5
| |
1
| |
NA
| |
Relative survival
|
1
| |
1
| |
0
| |
NA
| |
Metastasis-free survival
|
2
| |
2
| |
0
| |
NA
| |
Progression-free survival
|
1
| |
1
| |
0
| |
NA
| |
Biochemical recurrence-free survival
|
1
| |
1
| |
0
| |
NA
| |
Outcomes relating to neoplasms
|
19
|
7
|
18
|
6
|
1
|
1
|
0
|
0
|
(Change in) prostate-specific antigen (PSA) levels
|
3
| |
3
| |
0
| |
0
| |
Measurable disease response
|
1
| |
1
| |
0
| |
0
| |
Time to progression
|
2
| |
2
| |
0
| |
0
| |
Disease progression/Progression rate
|
2
| |
2
| |
0
| |
0
| |
Progression-free probability
|
1
| |
1
| |
0
| |
0
| |
Development of metastases
|
1
| |
1
| |
0
| |
0
| |
Metastases-free probability
|
1
| |
1
| |
0
| |
0
| |
Symptomatic skeletal event
|
1
| |
0
| |
1
| |
0
| |
Local disease
|
1
| |
1
| |
0
| |
0
| |
Positive surgical margins
|
1
| |
1
| |
0
| |
0
| |
Response duration
|
1
| |
1
| |
0
| |
0
| |
Failure-free probability
|
1
| |
1
| |
0
| |
0
| |
Development of castration-resistant disease
|
1
| |
1
| |
0
| |
0
| |
Treatment failure
|
2
| |
2
| |
0
| |
0
| |
Renal and urinary outcomes
|
13
|
6
|
8
|
3
|
3
|
2
|
2
|
1
|
Urinary incontinence
|
4
| |
2
| |
1
| |
1
| |
Urinary obstruction/irritation
|
3
| |
1
| |
1
| |
1
| |
Urinary symptoms
|
1
| |
0
| |
1
| |
0
| |
Voiding behaviour
|
1
| |
1
| |
0
| |
0
| |
Haematuria
|
1
| |
1
| |
0
| |
0
| |
Pelvic pain
|
1
| |
1
| |
0
| |
0
| |
Lymphedema
|
1
| |
1
| |
0
| |
0
| |
Urinary functioning
|
1
| |
1
| |
0
| |
0
| |
Gastrointestinal outcomes
|
6
|
5
|
3
|
2
|
2
|
2
|
1
|
1
|
Bowel symptoms
|
3
| |
0
| |
2
| |
1
| |
Faecal incontinence
|
1
| |
1
| |
0
| |
0
| |
Bowel functioning
|
1
| |
1
| |
0
| |
0
| |
Diarrhoea
|
1
| |
1
| |
0
| |
0
| |
Endocrine outcomes
|
3
|
3
|
0
|
0
|
2
|
2
|
1
|
1
|
Hormonal symptoms
|
3
| |
0
| |
2
| |
1
| |
Reproductive system outcomes
|
6
|
6
|
3
|
3
|
2
|
2
|
1
|
1
|
Erectile/sexual function
|
2
| |
2
| |
0
| |
0
| |
Erectile/sexual dysfunction (impotence)
|
3
| |
1
| |
1
| |
1
| |
Sexual symptoms
|
1
| |
0
| |
1
| |
0
| |
General outcomes
|
8
|
3
|
3
|
1
|
3
|
1
|
2
|
1
|
Pain
|
2
| |
0
| |
1
| |
1
| |
Fatigue
|
2
| |
0
| |
1
| |
1
| |
Bone pain
|
1
| |
1
| |
0
| |
0
| |
Weight loss
|
1
| |
1
| |
0
| |
0
| |
Anaemia
|
1
| |
1
| |
0
| |
0
| |
Performance status
|
1
| |
0
| |
1
| |
0
| |
Physical functioning
|
3
|
3
|
1
|
1
|
1
|
1
|
1
|
1
|
Physical wellbeing/functioning
|
3
| |
1
| |
1
| |
1
| |
Emotional functioning/wellbeing
|
4
|
4
|
2
|
2
|
1
|
1
|
1
|
1
|
Mental/emotional wellbeing/functioning
|
4
| |
2
| |
1
| |
1
| |
Social functioning
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
Social functioning
|
1
| |
1
| |
0
| |
0
| |
Role functioning
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
Role functioning
|
1
| |
1
| |
0
| |
0
| |
Global quality of life
|
6
|
6
|
6
|
6
|
0
|
0
|
0
|
0
|
Quality of life
|
6
| |
6
| |
0
| |
0
| |
Economic outcomes
|
2
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
Cost-effectiveness
|
1
| |
1
| |
0
| |
0
| |
Costs
|
1
| |
1
| |
0
| |
0
| |
Need for intervention
|
4
|
2
|
2
|
1
|
2
|
1
|
0
|
0
|
Need for salvage therapy
|
1
| |
1
| |
0
| |
0
| |
Need for curative treatment
|
1
| |
1
| |
0
| |
0
| |
Need for pain medication
|
1
| |
0
| |
1
| |
0
| |
Procedures need for local progression
|
1
| |
0
| |
1
| |
0
| |
Delivery of care
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
Time to treatment failure
|
1
| |
1
| |
0
| |
0
| |
Adverse events/effects
|
8
|
6
|
6
|
4
|
2
|
2
|
0
|
0
|
Adverse events
|
3
| |
2
| |
1
| |
0
| |
Perioperative deaths
|
1
| |
1
| |
0
| |
0
| |
Thromboembolic disease
|
1
| |
1
| |
0
| |
0
| |
Bothersome or symptomatic urethral or anastomotic stricture
|
1
| |
1
| |
0
| |
0
| |
Side-effects of hormonal therapy
|
1
| |
1
| |
0
| |
0
| |
Major systemic therapy effects
|
1
| |
0
| |
1
| |
0
| |
Total
|
103
| |
72
| |
22
| |
9
| |